Prana co-founder addresses US Senate
Tuesday, 08 July, 2008
The co-founder of Prana Biotechnology [ASX: PBT], Dr Rudolph Tanzi, has delivered testimony on Alzheimer's disease before the US Senate Special Committee on Ageing.
The hearings were held to discuss the growing crisis of Alzheimer's disease and to look for ways the US can accelerate its efforts against the disease.
Tanzi, an internationally recognised authority on Alzheimer's disease who co-discovered three of the four known genes that cause it, presented information on differing Abeta-targeted therapeutic approaches, and commented upon the ongoing clinical trials in Alzheimer's disease.
Prana's theories concerning the interaction between metals and the protein Abeta in the brain are the basis of the company's treatments for Alzheimer's and other neurodegenerative diseases.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
